Molecular marker MLLT11 for diagnosing and treating bladder cancer and application of molecular marker MLLT11

A technology of bladder cancer and markers, which is applied in the target and application fields of bladder cancer proliferation and metastasis research, and can solve the problems of lack of predictive indicators for bladder cancer and failure to improve the survival rate of bladder cancer patients

Inactive Publication Date: 2020-10-30
WENZHOU MEDICAL UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, there is still a lack of predictive indicators for the diagnosis of bladder cancer and early detection of metastasis, and the current clinical treatment methods have not improved the survival rate of bladder cancer patients, especially patients with advanced metastasis. Therefore, we urgently need to find new, more specific and sensitive methods Biological targets for predicting bladder cancer development and new targets for treating bladder cancer patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular marker MLLT11 for diagnosing and treating bladder cancer and application of molecular marker MLLT11
  • Molecular marker MLLT11 for diagnosing and treating bladder cancer and application of molecular marker MLLT11
  • Molecular marker MLLT11 for diagnosing and treating bladder cancer and application of molecular marker MLLT11

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1, MLLT11 is up-regulated in bladder cancer patients and bladder cancer cell lines

[0053] 1. Tissue samples

[0054] Tissue samples from 33 patients undergoing bladder cancer surgery were collected from March 2014 to December 2015, provided by the Urology Department of the First Affiliated Hospital of Wenzhou Medical University. Collect patient name, gender, age, pathology number, pathology and other information. Most of the selected patients were male and all underwent total cystectomy. Preoperative biopsy and postoperative pathological examination confirmed bladder urothelial carcinoma. Tumor tissue was collected from each sample, and normal tissue was cut about 3 cm away from the tumor as a control. Each sample was frozen in liquid nitrogen after the tissue was isolated, and the experimental operation was approved by ethical review.

[0055] 2. Immunohistochemistry

[0056] Refer to the immunohistochemical method, as follows:

[0057] 2.1. Baking slice...

Embodiment 2

[0088] Example 2. Analysis of TCGA database shows that the upregulation of MLLT11 expression is negatively correlated with the 5-year DFS and OS of bladder cancer patients

[0089] In order to clarify the possible role of MLLT11 in bladder cancer and the relationship with bladder cancer patients, the present invention analyzed the 5-year disease-free survival (DFS) and overall survival (OS) of bladder cancer patients in the TCGA database and the relationship between MLLT11 and MLLT11. The relationship between the amount of expression ( figure 2 A-2B), the median expression level of MLLT11 in bladder cancer tissues was used to divide them into two groups with high and low expression. The results showed that patients with low MLLT11 expression had longer 5-year DFS and 5-year OS and higher survival rate; on the contrary , patients with high expression of MLLT11 had shorter 5-year DFS and 5-year OS and lower survival rate, and there was a significant difference between the two g...

Embodiment 3

[0091] Example 3. Knocking out the expression of MLLT11 can significantly inhibit the proliferation ability of bladder cancer cells in vitro

[0092] 1) First, two commonly used bladder cancer cell lines T24T and UMUC3 were selected to construct MLLT11 knockout stable cell lines, and the Cas9 vector, MLLT11 KO#1, MLLT11 KO#2, and MLLT11 KO#3 plasmids were transfected into T24T and UMUC3 respectively Cells, stable cell lines obtained by monoclonal screening, western blot detection of MLLT11 protein level to confirm the knockout efficiency. The results showed that both T24T and UMUC3 cells successfully knocked out the expression of MLLT11 protein, and GAPDH was used as an internal reference ( Figure 3-1 ).

[0093] The sequence of MLLT11 KO#1 is shown in SEQ ID NO.1; the sequence of MLLT11 KO#2 is shown in SEQ ID NO:2; the sequence of MLLT11 KO#3 is shown in SEQ ID NO:3.

[0094] 2), soft agar colony formation experiment

[0095] A soft agar colony formation experiment was c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of MLLT11 as a specific marker in preparation of a medicine for diagnosing and treating bladder cancer. The invention further provides a kit for detecting the bladder cancer. The bladder cancer diagnosis kit comprises an antibody specifically combined with the MLLT11 protein. The invention further discloses application of an inhibitor of MLLT11 gene expression in preparation of a medicine for treating the bladder cancer.

Description

technical field [0001] The invention belongs to the field of biotechnology, and specifically relates to a new target for bladder cancer progression research and its application, and more specifically relates to MLLT11 as a bladder cancer proliferation and metastasis research target and its application. MLLT11 is used as a marker for bladder cancer diagnosis and prognosis, and the application of MLLT11 as a marker for bladder cancer in the preparation of molecular targeted drugs. Background technique [0002] According to the 2017 statistics of "cancer statistics", the world's authoritative journal of oncology, bladder cancer ranks fourth among malignant tumors in the United States, and approximately 16,870 patients die each year. The morbidity and mortality of bladder cancer rank first among urological tumors according to the analysis and evaluation of National Center for Cancer Registry (NCCR) in my country, and it has an upward trend in recent years. Clinically, bladder c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574A61K45/00A61K48/00A61K38/46A61P13/10A61P35/00A61P35/04
CPCA61K38/465A61K45/00A61K48/005A61P13/10A61P35/00A61P35/04G01N33/57407G01N33/5748
Inventor 金红蕾黄海山常园园孙文瑞
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap